Matthew W. Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Recognitions
Matthew W. Johnson has a total of 183 co-authors. Here are the top co-authors by number of shared publications:
- Justin Charles Strickland
Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Baltimore MD USA
12 shared publications Patrick S. Johnson
Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Suite 3000, Baltimore, MD, 21224, USA
11 shared publications- Roland R. Griffiths
Department of Psychiatry and Behavioral Sciences, Center for Psychedelic and Consciousness Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
10 shared publications - Albert Garcia-Romeu
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
9 shared publications - Mary Margaret Sweeney
Johns Hopkins University School of Medicine
8 shared publications Natalie R. Bruner
Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine
8 shared publications
Latest Publications
- Open Access
- 14 September 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (21) , 3462-3477
Next-Generation Psychedelic Drug Development
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.
- 14 September 2026
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 17 (21) , 3462-3477
Open AccessNext-Generation Psychedelic Drug Development
Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.
- Open Access
- 27 August 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (3)
Development of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire
Introduction: Interest in therapeutic applications of psychedelics has recently resurged. Mystical‐type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30‐item Mystical Experience Questionnaire (MEQ‐30) and the 26‐item Challenging Experience Questionnaire (CEQ), respectively. The brief 4‐item MEQ (MEQ‐4) and 7‐item CEQ (CEQ‐7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ‐4 and CEQ‐7. Methods: In translating the MEQ‐4 and CEQ‐7, our procedures were informed by the recommendations of the “Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient‐Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation.” Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese‐speaking sample with psychedelic experience was not feasible. Results: The final, approved back‐translated versions of the MEQ‐4 and CEQ‐7 were developed, and the authorized Japanese versions of the MEQ‐4 and CEQ‐7 were established. Conclusions: In the present study, Japanese versions of the MEQ‐4 and CEQ‐7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese‐speaking samples.
- 27 August 2026
- Published by Wiley in Neuropsychopharmacology Reports
- Vol. 46 (3)
Open AccessDevelopment of Japanese Versions of the 4‐Item Mystical Experience Questionnaire and 7‐Item Challenging Experience Questionnaire
Introduction: Interest in therapeutic applications of psychedelics has recently resurged. Mystical‐type and challenging experiences that are elicited by psychedelics are commonly assessed using the 30‐item Mystical Experience Questionnaire (MEQ‐30) and the 26‐item Challenging Experience Questionnaire (CEQ), respectively. The brief 4‐item MEQ (MEQ‐4) and 7‐item CEQ (CEQ‐7) may reduce respondent burden, but Japanese versions have not yet been developed. This study developed Japanese versions of the MEQ‐4 and CEQ‐7. Methods: In translating the MEQ‐4 and CEQ‐7, our procedures were informed by the recommendations of the “Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient‐Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation.” Separately, experts in psychedelics reviewed semantic nuances and the naturalness and appropriateness of the Japanese wording. Cognitive debriefing was not conducted because recruiting an appropriate Japanese‐speaking sample with psychedelic experience was not feasible. Results: The final, approved back‐translated versions of the MEQ‐4 and CEQ‐7 were developed, and the authorized Japanese versions of the MEQ‐4 and CEQ‐7 were established. Conclusions: In the present study, Japanese versions of the MEQ‐4 and CEQ‐7 were developed, enabling more rapid and efficient assessments of mystical and challenging experiences among Japanese speakers. Future studies should evaluate their comprehensibility, interpretability, cultural appropriateness, reliability, and validity in Japanese‐speaking samples.
- Open Access
- 30 April 2026
- Published by European Publishing in Tobacco Prevention & Cessation
- Vol. 12 (April) , 1-7
A descriptive content analysis of greenwashing tactics used in US cigarette advertisements between 2019–2023
Introduction: The tobacco industry has incorporated strategies like greenwashing (i.e. a marketing tactic that utilizes false or unverified claims to mislead consumers about a business's environmental practices and impact) within cigarette advertisements. Despite regulation to limit...
- 30 April 2026
- Published by European Publishing in Tobacco Prevention & Cessation
- Vol. 12 (April) , 1-7
Open AccessA descriptive content analysis of greenwashing tactics used in US cigarette advertisements between 2019–2023
Introduction: The tobacco industry has incorporated strategies like greenwashing (i.e. a marketing tactic that utilizes false or unverified claims to mislead consumers about a business's environmental practices and impact) within cigarette advertisements. Despite regulation to limit...
- Open Access
- 31 December 2025
- Published by SAGE Publications in Journal of Health Psychology
- Vol. 31 (9) , 3651-3667
Exploring self-reported health behavior change following naturalistic psychedelic use
Health-related behaviors are essential determinants of health and well-being, yet unhealthy patterns persist globally. Psychedelics may represent an innovative tool for facilitating positive behavior change. This study investigated retrospective health-related behavior changes attributed to past psychedelic experiences. An online survey was completed by 271 adults who reported on the characteristics of their most impactful psychedelic experience and associated changes across 74 behaviors, including physical activity, and time spent in nature. The most frequently reported changes were in contemplative practices (63%), time spent in nature (55%), and personally meaningful social activities (54%). The majority of changes were reported in a healthy direction. Higher ratings of perceived meaningfulness and having a set intention emerged as significantly associated with overall healthy change. While causality cannot be inferred, these findings highlight the potential of psychedelic experiences as catalysts for health-related behavior change and underscore the role of intention and perceived meaningfulness as candidate mechanisms.
- 31 December 2025
- Published by SAGE Publications in Journal of Health Psychology
- Vol. 31 (9) , 3651-3667
Open AccessExploring self-reported health behavior change following naturalistic psychedelic use
Health-related behaviors are essential determinants of health and well-being, yet unhealthy patterns persist globally. Psychedelics may represent an innovative tool for facilitating positive behavior change. This study investigated retrospective health-related behavior changes attributed to past psychedelic experiences. An online survey was completed by 271 adults who reported on the characteristics of their most impactful psychedelic experience and associated changes across 74 behaviors, including physical activity, and time spent in nature. The most frequently reported changes were in contemplative practices (63%), time spent in nature (55%), and personally meaningful social activities (54%). The majority of changes were reported in a healthy direction. Higher ratings of perceived meaningfulness and having a set intention emerged as significantly associated with overall healthy change. While causality cannot be inferred, these findings highlight the potential of psychedelic experiences as catalysts for health-related behavior change and underscore the role of intention and perceived meaningfulness as candidate mechanisms.
- Open Access
- 9 October 2025
- Published by Elsevier in Behavioural Processes
- Vol. 233, 105281
Time estimation variability in delay discounting: Model comparison and considerations
- 9 October 2025
- Published by Elsevier in Behavioural Processes
- Vol. 233, 105281
Open AccessTime estimation variability in delay discounting: Model comparison and considerations
- Top Cited Papers
- 30 May 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (4) , 172-191
Effects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions
Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy. Methods: Participants were psychedelic-naïve clergy from various major world religions. A randomized, parallel group, waitlist control design was used to assess the effects of two supported psilocybin sessions, with participants receiving 20 and then 20 or 30 mg/70 kg about 1 month later. Outcomes were compared between the Immediate Group ( n = 13) and the Delayed Group ( n = 16) at 6 months after screening using self-report measures. The effects of psilocybin were also assessed on session days and 4 and 16 months after the second psilocybin session in the 24 participants who completed both sessions. Results: The primary outcome assessment at 6 months after screening showed that, compared with the delayed control group, participants who had received psilocybin reported significantly greater positive changes in their religious practices, attitudes about their religion, and effectiveness as a religious leader, as well as in their non-religious attitudes, moods, and behavior. Follow-up assessments showed that positive changes in religious and non-religious attitudes and behavior were sustained through 16 months after the second psilocybin session. At that time, participants rated at least one of their psilocybin experiences to be among the top five most spiritually significant (96%), profoundly sacred (92%), psychologically insightful (83%), and psychologically meaningful (79%) of their lives. Furthermore, 42% rated one of their experiences to be the single most profound of their lifetime. At 16-months follow-up, most (79%) strongly endorsed that the experiences had positive effects on their religious practices (e.g., prayer or meditation) and their daily sense of the sacred, and most (71%) reported positive changes in their appreciation of religious traditions other than their own. Although no serious adverse events were reported, 46% rated a psilocybin experience as among the top five most psychologically challenging of their lives. Conclusions: In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.
- 30 May 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (4) , 172-191
Top Cited PapersEffects of Psilocybin on Religious and Spiritual Attitudes and Behaviors in Clergy from Various Major World Religions
Background: Although historical writings, anthropological accounts, and experimental studies document associations between psilocybin use and religion, no prospective experimental study has investigated how the effects of psilocybin are experienced and interpreted by religious clergy. This exploratory study evaluated the overall safety and the acute and enduring effects of psilocybin in clergy. Methods: Participants were psychedelic-naïve clergy from various major world religions. A randomized, parallel group, waitlist control design was used to assess the effects of two supported psilocybin sessions, with participants receiving 20 and then 20 or 30 mg/70 kg about 1 month later. Outcomes were compared between the Immediate Group ( n = 13) and the Delayed Group ( n = 16) at 6 months after screening using self-report measures. The effects of psilocybin were also assessed on session days and 4 and 16 months after the second psilocybin session in the 24 participants who completed both sessions. Results: The primary outcome assessment at 6 months after screening showed that, compared with the delayed control group, participants who had received psilocybin reported significantly greater positive changes in their religious practices, attitudes about their religion, and effectiveness as a religious leader, as well as in their non-religious attitudes, moods, and behavior. Follow-up assessments showed that positive changes in religious and non-religious attitudes and behavior were sustained through 16 months after the second psilocybin session. At that time, participants rated at least one of their psilocybin experiences to be among the top five most spiritually significant (96%), profoundly sacred (92%), psychologically insightful (83%), and psychologically meaningful (79%) of their lives. Furthermore, 42% rated one of their experiences to be the single most profound of their lifetime. At 16-months follow-up, most (79%) strongly endorsed that the experiences had positive effects on their religious practices (e.g., prayer or meditation) and their daily sense of the sacred, and most (71%) reported positive changes in their appreciation of religious traditions other than their own. Although no serious adverse events were reported, 46% rated a psilocybin experience as among the top five most psychologically challenging of their lives. Conclusions: In this population of clergy, psilocybin administration was safe and increased multiple domains of overall psychological well-being including positive changes in religious attitudes and behavior as well as their vocation as a religious leader. The study was limited by a waitlist control design, homogenous sample, and the use of some unvalidated outcome measures. Further research with more rigorous control conditions and diverse samples is needed.
- Open Access
- 26 May 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 189, 18-25
Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire
- 26 May 2025
- Published by Elsevier in Journal of Psychiatric Research
- Vol. 189, 18-25
Open AccessAdverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire
- 21 April 2025
- Published by Elsevier
- Vol. 181, 305-327
Psychedelics and substance use disorder treatment
- 21 April 2025
- Published by Elsevier
- Vol. 181, 305-327
Psychedelics and substance use disorder treatment
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 1-18
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information—but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes. Methods: To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents. Results: While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. Conclusions: : Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.
- 27 February 2025
- Published by SAGE Publications in Psychedelic Medicine
- Vol. 3 (1) , 1-18
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Introduction: Serotonergic psychedelics, serotonin 2A receptor agonists such as psilocybin that can result in substantially altered states of consciousness, are used in recreational and research settings. The safety of psychedelic experiences in research settings is supported by controlled physical environments, presence of clinical and medical staff to address emergent issues, screening for personal and family history of potential contraindications, and psychoeducational preparation with psychological support. Research settings typically provide psychoeducation to participants verbally and in writing (e.g., informed consent), and such documents and conversations can provide safety-related information—but may also introduce a wide range of expectancies. Such expectancies might involve the specific character of the acute subjective effects of psychedelics, possible side effects, and anticipated outcomes. Methods: To better understand the content of this psychoeducation, we gathered study materials from many psilocybin studies conducted in the past two decades in healthy and therapeutic populations. We conducted a reflexive thematic analysis to better understand these documents. Results: While these documents varied substantially between studies, we identified themes intended to lower levels of risk and optimize therapeutic effects from psychedelic treatments. The most frequently coded themes related to (1) biological and physical safety, (2) psychological safety and well-being, (3) aspects of setting, and (4) potential for expectancies. Prioritizing biological and psychological safety was evident in the materials from all sites. Furthermore, we identify potential contributors to expectancy unrelated to safety and suggest that these extrapharmacological elements be studied systematically in future research. Conclusions: : Ideally, future research should strive to maximize safety while attempting to minimize extraneous expectancies.
- 4 November 2024
- Published by Wiley in Journal of the Experimental Analysis of Behavior
- Vol. 122 (3) , 282-296
Experience with reduced‐nicotine cigarettes and whether this decreases smoking and substitution for full‐nicotine cigarettes
Studies suggest that reduced‐nicotine cigarettes decrease nicotine intake and dependence. However, questions remain about reduced‐nicotine cigarette abuse liability, whether reduced‐nicotine cigarette exposure lowers reduced‐ and full‐nicotine cigarette use, and whether reduced‐nicotine cigarettes substitute for full‐nicotine cigarettes. This randomized, double‐blind laboratory study used operant behavioral economics to examine abuse liability of cigarettes with varying nicotine content. Non‐treatment‐seeking smokers (N = 43) self‐administered reduced‐ (5.2, 2.4, or 1.3 mg/g) and full‐nicotine (15.8 mg/g) cigarettes before and after 3 weeks of at‐home exposure. Participants were randomized to full‐nicotine or one of the reduced‐nicotine cigarettes to determine the effect of exposure on abuse liability and substitutability. Abuse liability was assessed in single‐commodity sessions, and substitutability was measured in concurrent‐commodity sessions. In the self‐administration sessions, concurrently available reduced‐nicotine cigarettes attenuated full‐nicotine cigarette demand and rendered reduced‐nicotine cigarettes partial substitutes for full‐nicotine cigarettes. Exposure to study cigarettes for 3 weeks marginally reduced demand for reduced‐ and full‐nicotine cigarettes irrespective of nicotine content. Results suggest a limited influence of nicotine content on smoking behavior in established smokers and highlight the role of nonpharmacological factors (e.g., taste/smell) on the maintenance of smoking. These results should be considered in determining whether a nicotine‐reduction standard is a feasible path for reducing cigarette demand.
- 4 November 2024
- Published by Wiley in Journal of the Experimental Analysis of Behavior
- Vol. 122 (3) , 282-296
Experience with reduced‐nicotine cigarettes and whether this decreases smoking and substitution for full‐nicotine cigarettes
Studies suggest that reduced‐nicotine cigarettes decrease nicotine intake and dependence. However, questions remain about reduced‐nicotine cigarette abuse liability, whether reduced‐nicotine cigarette exposure lowers reduced‐ and full‐nicotine cigarette use, and whether reduced‐nicotine cigarettes substitute for full‐nicotine cigarettes. This randomized, double‐blind laboratory study used operant behavioral economics to examine abuse liability of cigarettes with varying nicotine content. Non‐treatment‐seeking smokers (N = 43) self‐administered reduced‐ (5.2, 2.4, or 1.3 mg/g) and full‐nicotine (15.8 mg/g) cigarettes before and after 3 weeks of at‐home exposure. Participants were randomized to full‐nicotine or one of the reduced‐nicotine cigarettes to determine the effect of exposure on abuse liability and substitutability. Abuse liability was assessed in single‐commodity sessions, and substitutability was measured in concurrent‐commodity sessions. In the self‐administration sessions, concurrently available reduced‐nicotine cigarettes attenuated full‐nicotine cigarette demand and rendered reduced‐nicotine cigarettes partial substitutes for full‐nicotine cigarettes. Exposure to study cigarettes for 3 weeks marginally reduced demand for reduced‐ and full‐nicotine cigarettes irrespective of nicotine content. Results suggest a limited influence of nicotine content on smoking behavior in established smokers and highlight the role of nonpharmacological factors (e.g., taste/smell) on the maintenance of smoking. These results should be considered in determining whether a nicotine‐reduction standard is a feasible path for reducing cigarette demand.